Press Releases

Date	Title and Summary	View
Sep 03, 2020	MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD , Sept. 03, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Aug 05, 2020	MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD , Aug. 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Jul 30, 2020	MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , July 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Jul 23, 2020	MacroGenics Announces Date of Second Quarter 2020 Financial Results Conference Call Rockville, MD , July 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Jul 09, 2020	MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer Rockville, MD , July 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that Lancet Oncology has published
Jun 22, 2020	MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting Rockville, MD , June 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American
Jun 16, 2020	MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer Rockville, MD , June 16, 2020 (GLOBE NEWSWIRE) -- Stephen Eck appointed Chief Medical Officer of MacroGenics MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of
Jun 05, 2020	MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer Rockville, MD , June 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S.
Jun 03, 2020	MacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia Rockville, MD , June 03, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced research published in the journal
May 28, 2020	MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer - Advisory committee meeting not required; PDUFA goal date unchanged Rockville, MD , May 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the
May 27, 2020	MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia Rockville, MD , May 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced plans for a clinical study intended to
May 21, 2020	MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO Rockville, MD , May 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a conference call and audio
May 13, 2020	MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting Rockville, MD , May 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary results from two of its
May 05, 2020	MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , May 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Apr 29, 2020	MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting Rockville, MD , April 29, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced three clinical presentations at the
Apr 28, 2020	MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format Rockville, MD , April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that its 2020 Annual Meeting of
Apr 28, 2020	MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call Rockville, MD , April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Apr 27, 2020	MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting Rockville, MD , April 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced data related to flotetuzumab, an
Mar 04, 2020	MacroGenics Announces Departure of Chief Medical Officer Rockville, MD , March 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that Jon Wigginton , M.D., Senior Vice
Feb 27, 2020	MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD , Feb. 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Feb 25, 2020	MacroGenics Provides Update on Corporate Progress and 2019 Financial Results Margetuximab: BLA for metastatic HER2-positive breast cancer accepted for review by the FDA; Phase 2/3 MAHOGANY study ongoing in front-line advanced HER2-positive gastric cancer First clinical data from Phase 1/2 studies of MGD013, MGC018 and MGD019 anticipated in 2020 Conference call scheduled for
Feb 13, 2020	MacroGenics Announces Date of Fourth Quarter and Full Year 2019 Financial Results Conference Call Rockville, MD , Feb. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Feb 10, 2020	MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD , Feb. 10, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Jan 13, 2020	MacroGenics to Present at the J.P. Morgan Healthcare Conference Rockville, MD , Jan. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will present at the
Jan 09, 2020	MacroGenics Outlines Corporate Priorities for 2020 Rockville, MD , Jan. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced its corporate and program priorities